Literature DB >> 3754600

1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20).

C Chouvet, E Vicard, M Devonec, S Saez.   

Abstract

1,25 (OH)2 D3 has been shown to be able to reduce the growth of several human cell lines. The effect of 1,25 (OH)2 D3 on the growth of breast cancer cell lines in relation to their oestrogen (ER) and progesterone (PGR) receptor content has been investigated. The growth inhibition of BT-20 and MCF-7 cell lines is related to the dose of 1,25 (OH)2 D3. It is dependent on the foetal calf serum concentration in the culture medium. At low concentration of 1,25 (OH)2 D3 the inhibitory effect is not detectable in the presence of 10% FCS. The rescue of cells from inhibition by serum was less effective when 1,25 (OH)2 D3 was present in the medium. The results of [3H]thymidine incorporation experiments and DNA measurements are in agreement with the reduction of cell number. Analysis in flow cytometry indicated a reduced number of cells in S phase. These data indicate that 1,25 (OH)2 D3 is able to modulate the growth of human breast adenocarcinoma cells regardless of their sex steroid dependency.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754600     DOI: 10.1016/0022-4731(86)90085-3

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  23 in total

1.  EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.

Authors:  Erin L Milliken; Xiaoxue Zhang; Chris Flask; Jeffrey L Duerk; Paul N MacDonald; Ruth A Keri
Journal:  Cancer Lett       Date:  2005-08-22       Impact factor: 8.679

Review 2.  Vitamin D and mammographic breast density: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz; Bettina Drake
Journal:  Cancer Causes Control       Date:  2011-10-08       Impact factor: 2.506

3.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

4.  Serum 25-hydroxyvitamin D levels in early and advanced breast cancer.

Authors:  C Palmieri; T MacGregor; S Girgis; D Vigushin
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

5.  A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1.

Authors:  Wenjie Xie; Yan He; Da Huo; Yafang Huang; Wei Wu
Journal:  Med Oncol       Date:  2009-12-15       Impact factor: 3.064

6.  Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.

Authors:  E Nolan; M Donepudi; K VanWeelden; L Flanagan; J Welsh
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

7.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

8.  CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Authors:  Puneet Dhawan; Robert Wieder; Robert Weider; Sylvia Christakos
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

9.  1alpha, 25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital.

Authors:  Mahendrakumar Chandrasekharappa Banakar; Suresh Kanna Paramasivan; Mitali Basu Chattopadhyay; Subrata Datta; Prabir Chakraborty; Malay Chatterjee; Kalaiselvi Kannan; Elayaraja Thygarajan
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

10.  1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  Y Iino; M Yoshida; N Sugamata; M Maemura; S Ohwada; T Yokoe; T Ishikita; R Horiuchi; Y Morishita
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.